Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Operating Leases (2019 - 2025)

Autolus Therapeutics' Operating Leases history spans 7 years, with the latest figure at $71.4 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 43.84% year-over-year to $71.4 million; the TTM value through Dec 2025 reached $71.4 million, up 43.84%, while the annual FY2025 figure was $71.4 million, 43.84% up from the prior year.
  • Operating Leases reached $71.4 million in Q4 2025 per AUTL's latest filing, up from $65.8 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $71.4 million in Q4 2025 to a low of $11.3 million in Q3 2022.
  • Average Operating Leases over 5 years is $40.8 million, with a median of $47.9 million recorded in 2023.
  • Peak YoY movement for Operating Leases: plummeted 67.28% in 2021, then surged 315.27% in 2023.
  • A 5-year view of Operating Leases shows it stood at $16.5 million in 2021, then grew by 16.16% to $19.2 million in 2022, then surged by 149.32% to $47.9 million in 2023, then rose by 3.58% to $49.6 million in 2024, then skyrocketed by 43.84% to $71.4 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Operating Leases are $71.4 million (Q4 2025), $65.8 million (Q3 2025), and $61.3 million (Q2 2025).